Skip to main content

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Publication ,  Journal Article
Hu, S; Xu-Monette, ZY; Balasubramanyam, A; Manyam, GC; Visco, C; Tzankov, A; Liu, W-M; Miranda, RN; Zhang, L; Montes-Moreno, S; Dybkær, K ...
Published in: Blood
April 4, 2013

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ∼14% of DLBCL patients. Patients with CD30(+) DLBCL had superior 5-year overall survival (CD30(+), 79% vs CD30(-), 59%; P = .001) and progression-free survival (P = .003). The favorable outcome of CD30 expression was maintained in both the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor κB activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30(+) DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30(+) DLBCL as a distinct subgroup of DLBCL.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

April 4, 2013

Volume

121

Issue

14

Start / End Page

2715 / 2724

Location

United States

Related Subject Headings

  • Vincristine
  • Treatment Outcome
  • Transcriptome
  • Survival Analysis
  • Rituximab
  • Prognosis
  • Prednisone
  • Multivariate Analysis
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hu, S., Xu-Monette, Z. Y., Balasubramanyam, A., Manyam, G. C., Visco, C., Tzankov, A., … Young, K. H. (2013). CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 121(14), 2715–2724. https://doi.org/10.1182/blood-2012-10-461848
Hu, Shimin, Zijun Y. Xu-Monette, Aarthi Balasubramanyam, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Wei-min Liu, et al. “CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.Blood 121, no. 14 (April 4, 2013): 2715–24. https://doi.org/10.1182/blood-2012-10-461848.
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu W-M, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJM, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 4;121(14):2715–2724.

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

April 4, 2013

Volume

121

Issue

14

Start / End Page

2715 / 2724

Location

United States

Related Subject Headings

  • Vincristine
  • Treatment Outcome
  • Transcriptome
  • Survival Analysis
  • Rituximab
  • Prognosis
  • Prednisone
  • Multivariate Analysis
  • Middle Aged
  • Male